4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose ...

Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher than in

Related Keywords

Park City ,Utah ,United States ,Florida ,Deerfield Beach ,Japan ,American ,Carl Danzig ,Katherine Smith ,Julian Pei ,Robert Kim ,Nasdaq ,Rand Eye Institute ,European Union ,Drug Administration ,Exchange Commission ,Linkedin ,American Society Of Retina Specialists ,American Society ,Retina Specialists ,Annual Scientific Meeting ,Molecular Therapeutics ,Dose Expansion ,Clinical Trials ,Chief Medical Officer ,Population Extension ,Injection Free Subgroup ,Scientific Meeting ,Therapeutic Vector Evolution ,Nobel Prize Winning ,Looking Statements ,Private Securities Litigation Reform Act ,Molecular Therapeutic ,Quarterly Report ,Investor Relations ,